AACC SPECIAL CONFERENCE IN CANCER RESEARCH
Cellular Responses to Environmental DNA Damage
December 1-6, 1991
Banff Springs Hotel, Banff, Alberta, Canada

CONFERENCE CO-CHAIRPERSONS
PHILIP C. HANAWALT / Stanford, CA
MALCOLM C. PATERSON / Edmonton, Alberta, Canada

SCIENTIFIC PROGRAM

Keynote Addresses
RICHARD B. SETLOW / Upton, NY
BRUCE N. AMES / Berkeley, CA

DNA Repair: Basic Mechanisms
LAWRENCE GROSSMAN / Baltimore, MD
ERROL C. FRIEDBERG / Dallas, TX
PHILIP C. HANAWALT / Stanford, CA
GWEN B. SANCAR / Chapel Hill, NC
BENNETT VAN HOUTEN / Burlington, VT

Lesions
BEA SINGER / Berkeley, CA
DOUGLAS E. BRASH / New Haven, CT
RUFUS S. DAY III / Edmonton, Alberta, Canada
ARTHUR P. GROLLMAN / Stony Brook, NY
RICHARD J. REYNOLDS / Los Alamos, NM
MUTSUO SEKIUCHI / Fukuoka, Japan
PETER SETLOW / Farmington, CT

Systems
JOHN M. BOYLE / Manchester, England
RONALD D. LEY / Albuquerque, NM
STUART LINN / Berkeley, CA
LOUISE PRAKASH / Rochester, NY
BARRY S. ROSENSTEIN / Providence, RI
BETSY S. SUTHERLAND / Upton, NY

Inducible Responses
WILLIAM L. CARRIER / Oak Ridge, TN
BRUCE DEMPLE / Cambridge, MA
ALBERT J. FORNACE, JR. / Bethesda, MD
GUY G. POIRIER / Sainte-Foy, Quebec, Canada
STEPHEN G. SEDGWICK / London, England
RONALD YASBIN / Baltimore, MD

Mutagenesis
BARRY W. GLICKMAN / Toronto, Ontario, Canada
JOHN M. ESSIGMANN / Cambridge, MA
VERONICA M. MAHER / East Lansing, MI
MICHAEL M. SEIDMAN / Rockville, MD
GRAHAM C. WALKER / Cambridge, MA

Human Population Response Heterogeneity
ROBERT H. HAYNES / Toronto, Ontario, Canada
RICHARD J. ALBERTINI / Burlington, VT
MICHAEL A. BENDER / Upton, NY
DANIEL W. NEBERT / Cincinnati, OH
THOMAS R. SKOPEK / Chapel Hill, NC
DAVID W. YANDELL / Boston, MA

Intragenomic DNA Repair Heterogeneity
VILHELM A. BOHR / Bethesda, MD
REGINALD A. DEERING / University Park, PA
DAREL J. HUNTING / Sherbrooke, Quebec, Canada
GEORGE J. KANTOR / Dayton, OH
LEON H. F. MULLENDERS / Leiden, Netherlands
MICHAEL J. SMERDON / Pullman, WA

Human Repair Gene Cloning
CHRISTINE A. WEBER / Livermore, CA
RICHARD A. GATTI / Los Angeles, CA
JOHN P. MURNANE / San Francisco, CA
KIYOSI TANAKA / Osaka, Japan
CRISTINE TROELSTRA / Rotterdam, Netherlands
GORDON F. WHITMORE / Toronto, Ontario, Canada

Human Genetic Disease
JAMES D. REGAN / Oak Ridge, TN
JAMES E. CLEAVER / San Francisco, CA
ALAN R. LEHMANN / Brighton, England
ROBERT W. MILLER / Bethesda, MD
MALCOLM C. PATERSON / Edmonton, Alberta, Canada
LARRY H. THOMPSON / Livermore, CA

Carcinogenesis
CURTIS C. HARRIS / Bethesda, MD
PETER A. CERUTTI / Épalinges, Switzerland
HELENE Z. HILL / Newark, NJ
ALAIN SARASIN / Villejuif, France
I. BERNARD WEINSTEIN / New York, NY

Aging
RONALD W. HART / Jefferson, AR
RAYMOND J. MONNAT, JR. / Seattle, WA
JOHN PAPACONSTANTINOU / Galveston, TX
KURT RANDERATH / Houston, TX
Y.-H. EUGENA WANG / Montreal, Quebec, Canada

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
Sixth and Chestnut Streets
Philadelphia, PA 19106
215-440-9300  215-440-9313 (FAX)

Deadline for Applications: September 16, 1991
EACR-XI
The Eleventh Biennial Meeting of the European Association for Cancer Research

Genoa, Italy
November 3-6, 1991

President, EACR
Peter Bannasch, Heidelberg

Chairman, EACR-XI National Scientific Committee
Leonardo Santi, Genoa

EACR-XI, the Eleventh official meeting of the European Association for Cancer Research, gathers together the most accomplished European and extra-European scientists in order to assess the most timely and promising findings and developments in the multidisciplinary field of basic cancer research. Plenary Lectures on fundamental issues followed by Parallel Symposia on related topics will provide the forum for engaging discussion and reflection.

Issues and Speakers to include:

Mühlbock Memorial Lecture: Olav Hilmar Iversen, Oslo
Special Guest Lecture: Paolo Fasella, Brussels

Plenary Lectures and Speakers

Immunodeficiency and Cancer Risk - Luigi Chieco Bianchi, Padua
New Biotechnologies in Cancer Immunotherapy - Antonio LanzaVecchia, Bascl
Rational Design of Sequence-specific Oncogene Inhibitors - Claude Hélène, Paris
Tumor Suppressor Genes and Their Mode of Action - George Klein, Stockholm
Hormones and Control of Gene Expression - Miguel Beato, Marburg

Parallel Symposia and Chairmen

Effector Cells against Cancer - Hans Wigzell, Stockholm
Biology of Melanomas - Gert Riemmüller, Munich
Cytogenetics of Solid Tumors - Avery Sandberg, Scottsdale
Biology of Tumor Invasion and Metastasis - Volker Schirrmacher, Heidelberg
Molecular Basis of Drug Resistance - Bridget Hill, London
Environmental Carcinogens and their Relevance to Humans - Benedetto Terracini, Turin
Tumor Drug Delivery - Siegfried Matzku, Darmstadt
Cancer Risk Assessment - Sandro Grilli, Bologna
Transgenic Mice as Tools for the Analysis of Multistage Carcinogenesis - Allan Balmain, Glasgow
Gene Alterations in Human Cancer Cells - Paolo Comoglio, Turin
New Approaches to Cancer Diagnosis and Management - Jo Hilgers, Amsterdam
Papilloma Viruses and Human Cancer - Harald zur Hausen, Heidelberg

In addition to regular poster display sessions, each Parallel Symposium will close with an hour long session dedicated to the special oral presentation of four Chairman selected posters dealing with relevant subject matter. Interested participants are invited to submit poster abstracts on Symposium related topics.

All abstracts will be published in a Supplement of the European Journal of Cancer.

Deadline for abstract submission is July 15th, 1991.

For information and appropriate registration/abstract forms, contact the EACR-XI Secretariat:

Istituto Nazionale per la Ricerca sul Cancro
Ufficio Rapporti Internazionali: Claudio Lombardo - Thomas Wiley
Viale Benedetto XV, n.10 - 16132 Genova ITALIA - Tel: +39/10/35 28 27 - Fax: +39/10/35 28 88
Concepts and Molecular Mechanisms of Multistage Carcinogenesis
First Joint Conference of the American Association for Cancer Research and the European Association for Cancer Research immediately following EACR-XI in Genoa

Additional Support from the Istituto Nazionale per la Ricerca sul Cancro

Grand Hotel Miramare, Santa Margherita, Italy
November 6-9, 1991

SCIENTIFIC PROGRAM COMMITTEE

AACR
I. BERNARD WEINSTEIN / New York, USA (Co-Chairperson)
ARTHUR P. GROLLMAN / Stony Brook, USA
HAROLD L. MOSES / Nashville, USA

EACR
PETER BANNASCH / Heidelberg, Germany (Co-Chairperson)
ALLAN BALMAIN / Glasgow, Scotland
JAN SVOBODA / Prague, Czechoslovakia

LOCAL ORGANIZING COMMITTEE

LEONARDO SANTI / Genoa, Italy (Chairperson)
MARIA COLNAGHI / Milan, Italy
MARGARET FOTI / Philadelphia, USA
CLAUDIO LOMBARDO / Genoa, Italy
MARCEL ROBERFROID / Brussels, Belgium

Welcoming Remarks
LEONARDO SANTI / Genoa, Italy

Opening Address
PETER BANNASCH / Heidelberg, Germany

Epidemiological and Experimental Evidence for the Multistage Process
HENRY C. PITOT / Madison, USA
ERICH HECKER / Heidelberg, Germany
FRANCO MERLETTI / Turin, Italy
FRIEDRICH MARKS / Heidelberg, Germany
FRANCIS V. CHISARI / La Jolla, USA

DNA Replication, Damage, and Repair
MARCEL ROBERFROID / Brussels, Belgium
DEZIDER GRUNBERGER / New York, USA
HARTMUT M. RABES / Munich, Germany
ARTHUR P. GROLLMAN / Stony Brook, USA
PHILIP C. HANAWALT / Stanford, USA
TOMAS LINDAHL / Herts, England
SARASWATI SUKUMAR / San Diego, USA

Multiple Genetic Changes during Tumor Development
LANCE A. LIOTTA / Bethesda, USA
JAN SVOBODA / Prague, Czechoslovakia
ALLAN BALMAIN / Glasgow, Scotland
ANTON BERSS / Amsterdam, The Netherlands
TERRY H. RABBITTs / Cambridge, England
WEBSTER K. CAVENEE / Montreal, Canada

Genetic Aspects of Tumor Suppression
GEORGE KLEIN / Stockholm, Sweden
ERIC J. STANBRIDGE / Irvine, USA
MARY WEISS / Paris, France
DAVID P. LANE / Herts, England
NICHOLAS HASTIE / Edinburgh, Scotland
EDWARD HARLOW / Charlestown, USA

Growth Factors and Signal Transduction
HAROLD L. MOSES / Nashville, USA
GIUSEPPE DELLA PORTA / Milan, Italy
CHRISTOPHER J. MARSHALL / London, England
CARL-HENRIK HELDIN / Uppsala, Sweden
RIK DERYNCK / South San Francisco, USA

Overview and Future Directions
I. BERNARD WEINSTEIN / New York, USA

APPLICATION FORMS (North and South America)
American Association for Cancer Research
Public Ledger Building, Suite 816
Sixth and Chestnut Streets
Philadelphia, PA 19106, USA
215-440-9300 215-440-9313 (FAX)

(Outside the Americas)
Italiana Congressi
Via Benss 2
16124 Genoa, ITALY
10-202541 10-299382 (FAX)

The AACR and EACR invite the international community of cancer researchers to submit applications for this exciting conference by August 15, 1991.

Abstracts for consideration for poster presentation also due by August 15, 1991.

A limited number of travel grants for graduate and medical students, postdoctoral fellows, and physicians in training will be available.
The Duke Comprehensive Cancer Center will celebrate its 20th anniversary in 1992. The 226 scientists and physicians who are members of the Center participate in a full spectrum of basic and clinical research, patient care, education, and cancer control. Basic cancer research is conducted in 72 research laboratories. Areas of particular interest include DNA repair, gene expression, receptor biology, lipid second messengers, viral oncology, acquired immunodeficiency syndrome (AIDS) research, and tumor immunology. Clinically oriented research programs concern autologous bone marrow transplantation, drug resistance, hyperthermia, neurooncology, pediatric oncology, and gynecological oncology. Each year more than 8000 cancer patients receive their care at the Duke University Medical Center and the immediately adjacent Durham Veterans Administration Medical Center.

William M. Shingleton, M.D., the founding director of the Center (left) is an alumnus of the Bowman Gray School of Medicine. In addition to a distinguished career in surgical oncology, Dr. Shingleton has served as a leader in many professional organizations, including the National Cancer Advisory Board and the American Cancer Society. With Dr. Shingleton’s guidance, the Center grew to its present size and several major buildings were constructed, including the Morris Clinical Cancer Research Building, the Jones Basic Cancer Research Building (pictured on cover), and the freestanding Cancer Center Isolation Facility, one of the largest P3-P4 facilities associated with a cancer center.

In 1987, Robert C. Bast, Jr., M.D. (center), succeeded Dr. Shingleton as director of the Duke Comprehensive Cancer Center. Having graduated magna cum laude from Harvard Medical School, Dr. Bast received additional training at Johns Hopkins Hospital, the National Cancer Institute, the Brigham and Women’s Hospital, and the Dana-Farber Cancer Institute. After a highly productive period on the staff of Dana-Farber, Dr. Bast moved to Duke in 1984 as codirector of Hematology-Oncology. His work has focused on the immunobiology and cell growth regulation of ovarian and breast cancer. Dr. Bast’s group developed the CA 125 assay for monitoring epithelial ovarian cancer. Using monoclonal reagents, he was also among the first to develop clinically useful techniques for the selective removal of leukemia, lymphoma, and breast carcinoma cells from human bone marrow to facilitate autologous transplantation. At Duke, he has pursued studies of heterogeneity in antigen expression, protooncogene activation, and growth-regulatory factors in ovarian and breast cancer.

Over the last four years, the Duke Comprehensive Cancer Center has been reorganized from a “matrix” to a “matrix-plus” with the establishment of the Section of Cell Growth, Regulation and Oncogenesis. Some 14 new scientists will be recruited directly into the Center through the Section to create a multidisciplinary team whose work concerns cell proliferation and differentiation. The Section is headed by Robert M. Bell, Ph.D., James B. Duke Professor of Biochemistry (right). Dr. Bell, the Deputy Director of the Center, received his Ph.D. from the University of California at Berkeley and joined the Duke faculty in 1972. He is widely recognized for important contributions to understanding the role of lipid second messengers in cellular regulation. His group’s studies of the regulation of protein kinase C by lipids led to the discovery that sphingolipid breakdown products may function as a new group of bioregulators. Their studies have also shown that ectopic expression of one isoform of protein kinase C can alter the growth of murine 3T3 cells and induce tumor formation. Dr. Bell is currently an associate editor of the Journal of Biological Chemistry.

Center facilities have been expanded, educational programs initiated, patient-oriented activities enhanced, and interaction with the community intensified. Some 19 shared instrumental resources have been established or upgraded with new facilities dedicated to the development of transgenic mice, high level radionuclide conjugation, X-ray crystallography, and two-dimensional gel electrophoresis. Educational programs extend from continuing medical education for physicians to summer programs for high school students.
Several novel patient-oriented programs have been developed, outpatient treatment facilities expanded, and construction of an adult outpatient residence begun. A National Cancer Institute-sponsored Cancer Information Service now answers inquiries from both North and South Carolina. A collaboration with the Florida Hospital in Orlando has provided a new model for affiliation between university-based cancer centers and outstanding community hospitals.

We are grateful to Dr. Bast and Stephanie Bass of the Duke Comprehensive Cancer Center for information and photographs.

Sidney Weinhouse